Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
Background For patients with advanced hepatocellular carcinoma, sorafenib is the only
approved drug worldwide, and outcomes remain poor. We aimed to assess the safety and …
approved drug worldwide, and outcomes remain poor. We aimed to assess the safety and …
Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study
Background Immune checkpoint inhibitors are a new standard of care for patients with
advanced non-small-cell lung cancer (NSCLC) without EGFR tyrosine kinase or anaplastic …
advanced non-small-cell lung cancer (NSCLC) without EGFR tyrosine kinase or anaplastic …
[HTML][HTML] Antitumor activity of nivolumab in recurrent and metastatic nasopharyngeal carcinoma: an international, multicenter study of the mayo clinic phase 2 …
Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An
International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742) - PMC Back …
International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742) - PMC Back …
Phase I/II safety and antitumor activity of nivolumab in patients with advanced hepatocellular carcinoma (HCC): CA209-040.
AB El-Khoueiry, I Melero, TS Crocenzi, TH Welling… - 2015 - ascopubs.org
LBA101 Background: Overexpression of PD-L1 in HCC has a poor prognosis. Safety and
preliminary antitumor efficacy of nivolumab, a fully human IgG4 monoclonal antibody PD-1 …
preliminary antitumor efficacy of nivolumab, a fully human IgG4 monoclonal antibody PD-1 …
[HTML][HTML] Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis
Background & Aims Nivolumab, an immune checkpoint inhibitor, is approved in several
countries to treat sorafenib-experienced patients with HCC, based on results from the …
countries to treat sorafenib-experienced patients with HCC, based on results from the …
[PDF][PDF] Nivolumab in sorafenib-naive and-experienced patients with advanced hepatocellular carcinoma: CheckMate 040 study
TS Crocenzi, AB El-Khoueiry, T Yau, I Melero… - J Clin …, 2017 - pdfs.semanticscholar.org
Nivolumab in Sorafenib-Naive and -Experienced Patients With Advanced Hepatocellular
Carcinoma: CheckMate 040 Study Page 1 Nivolumab in Sorafenib-Naive and -Experienced …
Carcinoma: CheckMate 040 Study Page 1 Nivolumab in Sorafenib-Naive and -Experienced …
Impact of antitumor activity on survival outcomes, and nonconventional benefit, with nivolumab (NIVO) in patients with advanced hepatocellular carcinoma (aHCC) …
AB El-Khoueiry, I Melero, TC Yau, TS Crocenzi… - 2018 - ascopubs.org
475 Background: NIVO (anti–PD-1 mAb) has demonstrated durable responses, long-term
OS, and manageable safety in pts with aHCC in CheckMate-040 (El-Khoueiry, Sangro et al …
OS, and manageable safety in pts with aHCC in CheckMate-040 (El-Khoueiry, Sangro et al …
[HTML][HTML] Povidone-iodine for the management of oral mucositis during cancer therapy
J Kanagalingam, A Chopra, MH Hong… - Oncology …, 2017 - ncbi.nlm.nih.gov
Oral mucositis (OM) is a common and often dose-limiting side effect of cancer therapy.
Povidone iodine (PVP-I) formulations have been shown to decrease the incidence and …
Povidone iodine (PVP-I) formulations have been shown to decrease the incidence and …
Abiraterone or Enzalutamide in Advanced Castration‐Resistant Prostate Cancer: An Indirect Comparison
A Chopra, M Georgieva, G Lopes, CM Yeo… - The …, 2017 - Wiley Online Library
BACKGROUND To perform a comparative effectiveness analyses between enzalutamide
and abiraterone acetate in both the pre‐docetaxel and post‐docetaxel settings based on …
and abiraterone acetate in both the pre‐docetaxel and post‐docetaxel settings based on …
Phase I/II safety and antitumor activity of nivolumab (nivo) in patients (pts) with advanced hepatocellular carcinoma (HCC): Interim analysis of the CheckMate-040 …
4012 Background: For pts with advanced HCC on sorafenib (sor), overall survival (OS) is 11
mo; median OS with best supportive care (BSC) post-sor failure is 7–8 mo. Safety and …
mo; median OS with best supportive care (BSC) post-sor failure is 7–8 mo. Safety and …